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A detailed understanding of the antibody response against SARS-CoV-2 is of high
importance, especially with the emergence of novel vaccines. A multiplex-based assay,
analyzing IgG, IgM, and IgA antibodies against the receptor binding domain (RBD), spike 1
(S1), and nucleocapsid proteins of the SARS-CoV-2 virus was set up. The multiplex-
based analysis was calibrated against the Elecsys® Anti-SARS-CoV-2 assay on a Roche
Cobas® instrument, using positive and negative samples. The calibration of the multiplex
based assay yielded a sensitivity of 100% and a specificity of 97.7%. SARS-CoV-2
specific antibody levels were analyzed by multiplex in 251 samples from 221 patients. A
significant increase in all antibody types (IgM, IgG, and IgA) against RBD was observed
between the first and the third weeks of disease. Additionally, the S1 IgG antibody
response increased significantly between weeks 1, 2, and 3 of disease. Class switching
appeared to occur earlier for IgA than for IgG. Patients requiring hospital admission and
intensive care had higher levels of SARS-CoV-2 specific IgA levels than outpatients. These
findings describe the initial antibody response during the first weeks of disease and
demonstrate the importance of analyzing different antibody isotypes against multiple
antigens and include IgA when examining the immunological response to COVID-19.
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• A multiplex based assay is as sensitive as the Elecsys® Anti-SARS-CoV-2 assay in detecting
SARS-CoV-2 specific IgG antibodies against N protein.
• SARS-CoV-2 specific antibodies class switch earlier to IgA than IgG in COVID-19 disease.
• Patients with high levels of SARS-CoV-2 specific IgA antibodies are more likely to be inpatients
or ICU patients.org June 2021 | Volume 12 | Article 6952301
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The need for a robust and clinically validated method to evaluate
the serological immune response against the SARS-CoV-2 virus
is of high importance. Both to elucidate the pathogenesis of
COVID-19 and to evaluate the efficacy of vaccines. In Iceland,
extensive testing, tracking, and surveillance for COVID-19 has
been performed. However, the true prevalence of COVID-19
might be higher than the number of cases confirmed by RT-PCR,
based on results from antibody screening of the Icelandic
population, where 56% of individuals positive for SARS-CoV-2
antibodies had been diagnosed by RT-PCR (1).
The immunological memory formed after COVID-19
infection and the persistence of antibodies is of great interest.
Studies have focused on antibodies against the spike protein,
especially the receptor binding domain (RBD) situated at the
spike1 (S1) subunit of the spike protein. Which is part of the
virus that connects to the Angiotensin-converting enzyme 2 on
the membrane of host cells (2). Studies have shown rapid
generation of anti-RBD IgG (3), anti-S (4) and antibodies
against the Nucleocapsid (N) protein (5). It has however been
shown that antibodies against different epitopes of the SARS-
CoV-2 virus (N protein and RBD) do not always correlate,
indicating that it is not always sufficient to measure only one
epitope (6). Cross-reacting antibodies that have been formed
against other coronaviruses, such as SARS-CoV-1, MERS or
other seasonal coronaviruses, can also be measured in tests
specific for SARS-CoV-2 due to the homology of the proteins (7).
The aim of the study was to calibrate a multiplex assay examining
the IgM, IgG, and IgA antibody levels against the immunogenic
antigens, i.e. the N, RBD and S1 proteins, of SARS-CoV-2 using the
commercial Elecsys® Anti-SARS-CoV-2 assay from Roche. The
calibrated assay was then used to analyze patients´ antibody
profiles and correlate them with disease outcomes.MATERIALS AND METHODS
Conjugation of Microspheres
RBD, N protein, and S1 (Trenzyme, Germany) were conjugated
to MagPlex® Microspheres (Luminex, USA) at a ratio of 3µg
protein/1*106 microspheres with NHS (50mg/ml) and EDC
(40mg/ml). Patient serum samples and serum pool were
incubated with microspheres at a 1:100 dilution, subsequently
with secondary antibodies for IgM, IgG and IgA and analyzed on
a Bioplex-200 machine (Bio-rad, USA). A more detailed protocol
can be found in the supplement.
Patient Samples
Clinical serum samples for calibration of the multiplex assay
were prospectively collected from the Department of Clinical
Microbiology. One hundred samples (disease not confirmed with
RT-PCR) were collected, 50 positive and 50 negative as measured
by Elecsys® Anti-SARS-CoV-2 on the Cobas e 411 analyzer
(Roche diagnostics).Frontiers in Immunology | www.frontiersin.org 2Negative controls, used to test for cross reactivity, were 36
pre-pandemic serum samples collected in 2019 by the
Department of Immunology.
The multiplex assay was normalized using a serum pool (MFI
of sample/MFI of serum pool), consisting of serum from 46
healthy blood donors, collected in august 2018, aliquoted and
stored at -80°C.
All COVID-19 patient samples received by the Department of
Immunology (251 samples, from 221 RT-PCR confirmed
COVID-19 patients), from February – May 2020 were
analyzed. Patient demographics and sampling times from self-
reported start of symptoms are shown in Supplementary
Table 1.
All COVID-19 patients received medical care and follow-up
for the duration of their illness and/or isolation.
The study was approved by The National Bioethics
Committee (VSN-20-169) and the Data Protection Authority.
Statistical Analysis
Results are presented as mean ± standard deviation (SD). Two-
way ANOVA and Kruskal-Wallis tests were used when
appropriate. Differences were considered statistically significant
when p<0.05. Analysis was performed on GraphPad Prism 9
(GraphPad, USA).RESULTS AND DISCUSSION
The Multiplex Serologic Assay Is of High
Reliability and Validity
SARS-CoV-2 IgG antibodies against N protein were blindly
analyzed using the multiplex assay in 100 prospectively
collected samples from the Department of Clinical
Microbiology, previously analyzed by the Elecsys® Anti-SARS-
CoV-2 assay (Figure 1A).
The samples were normalized by dividing the median
fluorescence intensity (MFI) of the samples with the MFI from
a serum pool provided by the Icelandic Blood bank. After
normalizing measurements from the multiplex assay, a sample/
pool ratio of 4 for IgG antibody ratio against the N protein was
found to discriminate between IgG positive and negative
samples, with 99 of 100 results in agreement with the Elecsys®
Anti-SARS-CoV-2 assay (Figure 1A). Therefore, a ratio of 4 was
used as a cut-off value to discriminate between positive and
negative samples. This cut-off value was applied to the S1, RBD
proteins and against the IgA and IgM isotypes as well.
The single discordant sample that was negative in the Elecsys®
but positive in the multiplex had a sample/pool ratio >4 (4.83)
in IgG for N protein. The multiplex also showed a >4
IgM ratio against both RBD and N protein (14.74 and 13.12,
respectively) and a >4 IgG and IgA RBD ratio (28 and 4.74,
respectively) (Figure 1A). These results indicate that this sample
came from an individual early in disease that is undergoing class
switching. Additionally, differences in incubation times between
Elecsys and the multiplex assay (9 min vs. 30 min) may play a role,June 2021 | Volume 12 | Article 695230
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with a lower affinity.
Several negative samples were close to the cut-off (sample/
pool ratio 2-4 in multiplex assay). A ratio >4 for IgM RBD and
IgA RBD was detected in 3 out of the 4 samples and 1 out of 4
samples had >4 ratio of IgG RBD. These results suggest that these
samples were undergoing class switching from IgM antibodies
towards IgG and IgA, suggesting that a ratio of 4 might be too
stringent, resulting in false negative outcomes (Figure 1A).
SARS-CoV-2 IgG specific antibodies against N protein were
analyzed in 36 pre-pandemic serum samples. One case had a
sample/pool ratio >4 (Figure 1B). Further analysis revealed a
different pattern than for the COVID-19 samples, with no
increase in IgM or IgA levels. This might reflect a previous
infection with a different coronavirus due to the known potential
cross-reactivity of the N protein for this virus (8).
Using results from the Elecsys® assay and pre-pandemic samples
as true positive and negative, the calculated sensitivity and specificityFrontiers in Immunology | www.frontiersin.org 3of the multiplex assay for IgG against N protein by applying a >4
sample/pool ratio, was 100% and 97.7%, respectively.
These results indicate that the multiplex assay is a sensitive
and specific method for detecting SARS-CoV-2 specific IgG
antibodies against the N protein.Class Switching in SARS-CoV-2 Infected
Individuals Occurs Faster for IgA
Than for IgG
SARS-CoV-2 specific IgM, IgG, and IgA antibodies against RBD,
N, and S1 were analyzed in 251 samples from 221 COVID-19
patients using the multiplex assay (Figure 2A). For RBD, a
significant rise in antibody levels for IgM, IgG, and IgA was seen
when comparing samples taken during week 1, 2, and week 3.
For IgA, samples from week 1 showed a significantly lower ratio
than weeks 2 and 3. For S1, the ratio increased significantly for
IgG between weeks (Figure 2A).A
B
FIGURE 1 | SARS-CoV-2 antibody levels as measured by a multiplex based assay and calibrated against the Elecsys® Anti-SARS-CoV-2 assay (Roche
diagnostics). (A) 100 serum samples previously analyzed by Elecsys® assay (depicted on the x axis as negative and positive), were received from the
Department of Clinical Microbiology, and SARS-CoV-2 IgG antibodies against the N protein were analyzed blindly by multiplex (left panel). Right top panel
depicts the single sample that had a SARS-CoV-2 IgG >4 sample/pool ratio for the N protein. Bottom right panel depicts the samples that showed a >2 but <4
than 4 sample/pool ratio by multiplex. (B) Left panel depicts 36 serum samples received in 2019 by the Department of Immunology. SARS-CoV-2 IgG
antibodies against the N protein were analyzed by multiplex. Right panel depicts the serum/pool ratio of the serum samples against RBD, S1 and N proteins.
Samples above the cut-off level are color coded.June 2021 | Volume 12 | Article 695230
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were considered IgM negative (ratio below 4) for all three
proteins (Figure 2B). For IgG and IgA, 39/58 and 30/58 were
negative, respectively. However, during week 3, only 6 of 45
samples were IgM negative for all three proteins, while 10 and 9
were negative for IgG and IgA, respectively. During the third
week the majority of patients had thus undergone class
switching, which seemed to occur faster for IgA than IgG (16
negative for IgA and 46 negative for IgG during week 2).
Out of 221 COVID-19 patients, 35 (15.8%) cases did not reach
the defined cut-off level for IgM, IgG, or IgA for any of the three
proteins (17/58 week 1, 12/113 week 2, 6/45 week 3, 0/35 > week
3). However, a cut-off ratio of >4 ratio might be unnecessarily
restrictive, decreasing sensitivity early on in disease.
Patients admitted to intensive care showed higher IgA ratios
for RBD and S1 when compared to the outpatient group, while
both inpatients and intensive care patients showed higher IgA
ratios for N protein than outpatients (Figure 2C). IgG and IgM
did not show any statistical differences between patient
groups. Most of the intensive care patients were admittedFrontiers in Immunology | www.frontiersin.org 4within the first 2 weeks of disease (1 during week 1, 8 during
week 2, 4 during week 3 with an average of 12.69 days after self-
reported start of symptoms, Supplementary Table 1).
Our findings are in agreement with previous reports on a high
IgA levels, both total (9) and SARS-CoV-2 specific IgA (5, 10,
11), in patients with more severe COVID-19 disease. High viral
load in the respiratory mucosa has been associated with more
severe symptoms (12) and a more robust IgA response might
also indicate a more aggressive disease and worse outcome.
There was a clear difference in the antibody profile between
samples from patients infected with SARS-CoV-2 and samples
from patients with cross-reactive antibodies against one or more
of the proteins. Showing that this method can discriminate
between individuals that are infected with SARS-CoV-2, and
non-infected individuals showing cross-reactive antibodies.
This study examines multiple antibody isotypes, against
multiple SARS-CoV-2 antigens in 221 COVID-19 patients
with varying disease severity at early timepoints in the disease
were examined. Of the 3 antigens tested, RBD seemed to be the
most immunogenic. Interestingly, following the initial IgMA B
C
FIGURE 2 | SARS-CoV-2 specific antibody levels against the RBD, S1, and N proteins in 221 COVID-19 patients. (A) Depicting the mean and standard deviation in
sample/pool ratio of SARS-CoV-2 antibody levels for IgM, IgG, and IgA for weeks 1, 2, 3 and over 3 weeks. (B) Venn diagram showing the number of patients with a
ratio >4 for IgM, IgG, and IgA against the RBD, S1 and N proteins. Patients below the cut-off value of 4 in ratio against all proteins are depicted as neg in the bottom
right corner of each diagram. 35 out of the 251 samples were below 4 for all the proteins, for the three antibody isotypes. (C) The IgA sample/pool ratio in COVID-19
outpatients (n=168), inpatients (n=40), and ICU patients (n=13). *, **, *** and **** correspond to p=<0.05, p=<0.01, p<0.001 and p=0.0001, respectively.June 2021 | Volume 12 | Article 695230
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IgG. Finally, a more robust IgA response was found in patients
with severe disease requiring ICU admission.
CONJUGATION OF MICROSPHERES
SARS-CoV-2 proteins S1, RBD, and N (all from Trenzyme,
Konstanz, Germany), were conjugated to MagPlex® Microspheres
(Luminex Corporation, Austin, Texas, USA) at a ratio of 3µg
protein/1*106 microspheres. Microspheres were washed using a
magnet (vortex and sonication was included with each wash) twice
with an activation buffer (100mM NaH2PO4 in water, pH 6.0).
Microspheres were resuspended in activation buffer, Sulfo-NHS
(50mg/ml) and EDC (40mg/ml) were added to the microspheres
and incubated in dark on a rotator for 20 min. Microspheres were
washed three times with coupling buffer (50mM MES, pH 5.0).
Microspheres were resuspended in coupling buffer, protein added
and incubated on rotor for two hours. Microspheres were washed
three times and resuspended with blocking buffer (PBS, 1%
newborn bovine serum (NBBS), 0.08% Azide, sterile), and stored
in dark and 4°C until use.
ASSAY
Briefly, 2500 microspheres for each protein were added to each
well in 3x96 well plates (one for each isotype) and washed in a
Bio-Plex Pro (Bio-Rad, Hercules, California, USA) wash station.
Serum samples, both the serum pool and patient samples, were
diluted 1/100 with PBS with 2% NBBS and incubated with the
microspheres for 30 min/RT/shaking in the dark. Plates are
washed and secondary antibodies are added in a 1/100 dilution
(diluted in PBS-T with 2% NBBS), then incubated for 30 min/
RT/shaking in the dark (anti-IgA-PE is from Southern Biotech,
Birmingham, Alabama, anti-IgG-PE and anti-IgM-PE from
Jackson ImmunoResearch, West Grove, Pennsylvania, USA).
Microspheres are resuspended after wash in PBS-T with 2%
NBBS and analyzed on a Bio-plex 200 (Bio-Rad).
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.Frontiers in Immunology | www.frontiersin.org 5ETHICS STATEMENT
The study was approved by The National Bioethics Committee
(VSN-20-169) and the Data Protection Authority. Written
informed consent for participation was not required for this
study in accordance with the national legislation and the
institutional requirements.AUTHOR CONTRIBUTIONS
SB and HS: designed the research, measured samples, analyzed data,
and wrote the manuscript. SS and BL: designed research and wrote
the manuscript. EE: measured samples. GBj: designed research and
wrote the manuscript. BA, GBa, AL, and KK: provided serum
samples and Elecsys measurements. AB and OG: provided clinical
data. SG: provided the serum pool. All authors contributed to the
article and approved the submitted version.FUNDING
This work was supported in part by The Student Innovation
Fund. The funding body had no role in the design of the study,
collection, analysis, interpretation of data or writing of
the manuscript.ACKNOWLEDGMENTS
We would like to thank Runólfur Pálsson and Elıás Eyþórsson
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